CHATSWORTH, Calif.--(BUSINESS WIRE)--North American Scientific, Inc. (Nasdaq:NASI) today announced that its ClearPath-HDR device has been used in a patient for the first time.
For use in Accelerated Partial Breast Irradiation (APBI) treatment plans, ClearPath-HDR combines the ease-of-use benefits of balloon brachytherapy products with the customized dose planning benefits of the multi-catheter brachytherapy procedure into one device. This innovative combination also allows doctors to take advantage of a shorter five-day APBI treatment plan, compared with the six to eight weeks required for external beam treatment plans. In addition, ClearPath is implanted through a single incision and is designed to minimize radiation exposure of nearby healthy tissue, two key patient benefits, which distinguish this product from others on the market.
